Status:
COMPLETED
Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Varicella
Eligibility:
All Genders
12-23 years
Phase:
PHASE3
Brief Summary
This study will test the safety, tolerability, and immunogenicity of VARIVAX manufactured with the 2007 commercial Varicella-Zoster Virus (VZV) bulk process when concomitantly administered with M-M-R ...
Detailed Description
This treatment has been approved for sale to the public.
Eligibility Criteria
Inclusion
- Subject is in good health based on medical history
- Subject has no history of measles, mumps, rubella, chickenpox, or shingles
Exclusion
- Subject has previously received measles, mumps, rubella, and/or varicella vaccine either alone or in combination
- Subject has history of immune disorders
- Subject has been exposed to chickenpox/shingles, measles, mumps, rubella or varicella within 4 weeks of study start
- Subject has received an inactivated vaccine within 14 days of first dose of study vaccine
- Subject has received a live vaccine within 30 days of first dose of study vaccine
- Subject has received a blood transfusion or blood-derived products within 3 months of receiving study vaccine
- Subject has had a fever within 72 hours of study start
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
598 Patients enrolled
Trial Details
Trial ID
NCT00822237
Start Date
January 1 2009
End Date
December 1 2009
Last Update
April 12 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.